The obesity pipeline: current strategies in the development of anti-obesity drugs.
about
4-Hydroxyisoleucine from Fenugreek (Trigonella foenum-graecum): Effects on Insulin Resistance Associated with ObesityNew and emerging drug molecules against obesity.Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.The endocannabinoid system: a new pharmacological target for obesity treatment?Prieurianin Causes Weight Loss in Diet-Induced Obese Mice and Inhibits Adipogenesis in Cultured Preadipocytes.Beta-arrestin-based Bret2 screening assay for the "non"-beta-arrestin binding CB1 receptor.Selection of aptamers for mature white adipocytes by cell SELEX using flow cytometry.kappa-Opioid receptors control the metabolic response to a high-energy diet in miceEffects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model.Isoxazol-5(4H)one derivatives as PTP1B inhibitors showing an anti-obesity effect.The small molecule indirubin-3'-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice.A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysPharmacological treatment of obesity in children and adolescents: present and futureInvestigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjectsDrosophila ste-20 family protein kinase, hippo, modulates fat cell proliferation.Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase.Modafinil decreases food intake in humans subjected to simulated shift work.Anti-obesity effects of Yerba Mate (Ilex Paraguariensis): a randomized, double-blind, placebo-controlled clinical trial.Curcumin Mimics the Neurocognitive and Anti-Inflammatory Effects of Caloric Restriction in a Mouse Model of Midlife Obesity.Using Animal Models to Determine the Role of Gustatory Neural Input in the Control of Ingestive Behavior and the Maintenance of Body Weight.Total control of fat cells from adipogenesis to apoptosis using a xanthene analog.Anti-obesity effects of Rapha diet® preparation in mice fed a high-fat diet.Sirt1 protects against high-fat diet-induced metabolic damage.Drug discovery in the metabolic syndrome: context and some recent developments.Medical weight loss treatment options in obese solid-organ transplant candidates.Fat synthesis and adiposity regulation in Caenorhabditis elegansEffect of Gambisan on the Inhibition of Adipogenesis in 3T3-L1 AdipocytesReview paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress.Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes.Neuropsychiatric adverse effects of centrally acting antiobesity drugs.Anti-obesity drugs: past, present and future.Managing cardiovascular risk in overweight children and adolescents.Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity.New therapeutic approaches for the treatment of obesity.Further brominated polyacetylenes with pancreatic lipase inhibitory activity from Chinese marine sponge Xestospongia testudinaria.Transcriptome Profile Reveals that Pu-Erh Tea Represses the Expression of Vitellogenin Family to Reduce Fat Accumulation in Caenorhabditis elegans.Effect of germinated brown rice extracts on pancreatic lipase, adipogenesis and lipolysis in 3T3-L1 adipocytes.Oligopeptide complex for targeted non-viral gene delivery to adipocytes.
P2860
Q28072896-6E236C22-309E-44A6-A16E-039C7C58378BQ30353872-41C52275-7726-427E-A20D-AC16BF707D73Q30366778-72279BF6-A91C-4F71-9D2E-F59DB082E85AQ30377157-817A16F2-307D-4B82-8E91-76517C83BD32Q30402685-FFDCA896-464C-4988-B6EE-08CE9EA97428Q33436593-D3231F99-8683-4DC8-A2F4-AF317D298B1BQ33638456-592C21FA-4018-4042-AF2F-ED0E629D7050Q33752916-E80875B7-C82F-4C69-AF6A-2D31B7DE165AQ33838889-549E354D-2DD8-4658-952E-30E28E83FB4EQ33927742-F4768A13-B94E-43B5-9BFA-68D8A7099FB9Q34018084-E4555CA7-648F-4C9D-9378-E511E0726095Q34181302-9954F84A-B2AF-46BF-B706-A75549C9C36EQ34231426-100E3096-6CAA-4209-92C5-AA001A364A1AQ34442880-1AE9ADC6-F9A9-48AC-8A12-0403A9B7B1C6Q34677765-C69DA772-76D2-4629-8B0B-BFD11EF466D7Q34700613-209C2A62-4A42-4414-954A-71B30EDFDBDFQ34770053-AD3843D2-5EA0-4FB2-AEC7-50CC415CEBA3Q34788366-AE90322E-3F64-49B8-B6E9-767CABFF3151Q35789142-C28A5FCB-FC94-4BBC-BF60-B29AB582656AQ35810301-4F90FEEB-80BE-418C-A766-D6C9EE3A88E0Q36257164-E03A0132-1727-4A87-9104-3781D70A55E8Q36393023-87CC6005-D7FE-4875-A464-0BE76EFBFA18Q36524504-4C7FEECD-793D-42E8-B078-EFA5173B6108Q36775324-41CD940A-F1FA-4BCC-A54C-371C62F8C5B0Q36822448-1A83071E-1E00-4D87-BB17-BFA4B47007EBQ36955943-48755835-5A9A-415D-8CBB-234039E2571DQ37151126-6633BC51-078A-469B-AB0C-68102872A4AAQ37171896-0F39CFBA-6722-411E-9ED1-0A40FDDEB10BQ37359377-9DE6206E-0A2A-44A7-B7E7-315D6DAFD44EQ37644382-8B8E4002-28CF-4809-83C6-11E5C5AABD61Q37760961-7E4F69C5-3F5C-49A9-9F87-50001DDB7EE0Q37939362-8FADD1AE-030E-48E6-9BCB-453BB64848C5Q38036925-075978EB-185C-4BF5-B5BE-854C38460B05Q38098481-C4218CE7-80A8-420D-8DE4-999FF4079D83Q38099388-037D5DE4-D4BB-493B-B6A1-509A62DAC32DQ38714562-FFB623BE-41C8-471A-9207-F2832581B7E8Q38983789-B47EEA01-D158-421C-990E-F07FDA9BCB01Q39267383-20CBADDE-014D-4851-8B77-CEF2E3A2BC4EQ41881435-3C0CC9EC-2639-4867-A325-DAEE6A84A764Q42184688-7C8BB595-313F-47A4-8B1C-68CC21FDA69E
P2860
The obesity pipeline: current strategies in the development of anti-obesity drugs.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@ast
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@en
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@nl
type
label
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@ast
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@en
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@nl
prefLabel
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@ast
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@en
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@nl
P356
P1476
The obesity pipeline: current strategies in the development of anti-obesity drugs.
@en
P2093
Dunstan Cooke
Steve Bloom
P2888
P304
P356
10.1038/NRD2136
P577
2006-11-01T00:00:00Z